Unique Benefits of Nanotechnology to Drug Delivery and Diagnostics

Methods in Molecular Biology

Volumn 697, Issue , 2011, Pages 3-8

  McNeil, Scott E ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

active and passive targeting; efficacy; nanomedicine; Nanoparticles; toxicity

Indexed keywords

DRUG; NANOMATERIAL; NANOPARTICLE;

ANIMAL; ARTICLE; CHEMISTRY; DRUG DELIVERY SYSTEM; HUMAN; METHODOLOGY; NANOMEDICINE; NANOTECHNOLOGY; SURFACE PROPERTY;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOPARTICLES; NANOSTRUCTURES; NANOTECHNOLOGY; PHARMACEUTICAL PREPARATIONS; SURFACE PROPERTIES;

MLCS; MLOWN;

EID: 79952841575     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60327-198-1_1     Document Type: Chapter

References (11)

1. http://www.nano.gov/html/facts/whatIs Nano.html
2. Harris, J.M., Chess, R.B. (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2, 214–21.
3. Fang, J., Sawa, T., Maeda, H. (2003) Factors and mechanism of “EPR” effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 519, 29–49.
4. Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65, 271–84.
5. Sahoo, S.K., Labhasetwar, V. (2003) Nanotech approaches to drug delivery and imaging. Drug Discov Today 8, 1112–20.
6. Ravi Kumar, M., Hellermann, G., Lockey, R.F., Mohapatra, S.S. (2004) Nanoparticle-mediated gene delivery: state of the art. Expert Opin Biol Ther 4, 1213–24.
7. Paciotti, G.F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R.E., Tamarkin, L. (2004) Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 11, 169–83.
8. Desai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., Noker, P., Yao, R., Labao, E., Hawkins, M., Soon-Shiong, P. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12, 1317–24.
9. Green, M.R., Manikhasm, G.M., Orlovm, S., Afanasyev, B., Makhson, A.M., Bhar, P., Hawkins, M.J. (2006) Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17, 1263–8.
10. Patri, A.K., Kukowska-Latallo, J.F., Baker, J.R. Jr. (2005) Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev 57, 2203–14.
11. Huwyler, J., Wu, D., Pardridge, W.M. (1996) Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93, 14164–9.